Patent · US Active

Cells comprising non-HLA restricted T cell receptors

US12036244B2 · kind B2 · utility

0Cited by
7References
21Claims
0Family size

Assignee

Inventors

Key dates

Filing dateOct 19, 2021
Grant dateJul 16, 2024
Priority date
Expiry dateOct 19, 2041

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2510/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The presently disclosed subject matter provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to novel designs of T cell receptors (TCRs) and engineered immunoresponsive cells comprising the same. The novel TCR binds to an antigen in an HLA-independent manner. In certain embodiments, the novel TCR provides enhanced sensitivity for a target gene having a low expression level.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.